Dupilumab normalizes the eosinophilic esophagitis disease transcriptome

ABSTRACT: Dupilumab, which blocks interleukin (IL)-4 and IL-13 signaling, is approved in eosinophilic esophagitis (EoE) and several other type 2 inflammatory diseases. We show that dupilumab normalizes the dysregulated esophageal transcriptome in pediatric, adolescent, and adult patients with EoE, including both eosinophil-related and eosinophil-independent biologic pathways.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303734 | GEO | 2025/10/01

REPOSITORIES: GEO